Prior notification of a concentration (Case COMP/M.4418 — Nycomed Group/Altana Pharma) Text with EEA relevance 
Prior notification of a concentration 
(Case COMP/M.4418 — Nycomed Group/Altana Pharma) 
(2006/C 283/04) 
(Text with EEA relevance) 
1. On 8 November 2006, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1] by which the undertaking Nycomed Group (%quot%Nycomed%quot%, Denmark) jointly controlled by Nordic Capital Fund V (%quot%Nordic Capital%quot%, Jersey) and Credit Suisse Group (%quot%CSG%quot%, Switzerland) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Altana Pharma AG (%quot%Altana%quot%, Germany) by way of purchase of shares. 
2. The business activities of the undertakings concerned are: 
- for Nycomed: manufacturing and sale of hospital products and pharmaceuticals; 
- for Altana: research, development, manufacturing and sale of pharmaceuticals; 
- for Nordic Capital: private equity fund; 
- for CSG: global financial services group. 
3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. 
4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. 
Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4418 — Nycomed Group/Altana Pharma, to the following address: 
European Commission 
Directorate-General for Competition 
Merger Registry 
J-70 
B-1049 Bruxelles/Brussel 
[1] OJ L 24, 29.1.2004, p. 1. 
-------------------------------------------------- 
